Peritoneal carcinomatosis(PC)is the second most common presentation of colorectal cancer distant metastasis.Despite remarkable advances in cytotoxic chemotherapy and targeted therapy for colorectal cancer recently, it has been shown that these therapies remain ineffective for colorectal cancer PC.There have beensome reports that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy(CRS/HIPEC)improved the overall survival of colorectalcancer PC patients.Here, we reviewed the clinical presentation, the mechanisms of disease progression and current treatment options for colorectal cancer PC, with a focus on the benefits and limitations of CRS/HIPEC.Moreover, we collected the patients with colorectal cancer PC treated by CRS/HIPEC in our colorectal cancer center, and showed that morbidity and mortality of CRS/HIPEC is relatively low, and short-term quality of life may improve.In conclusion, CRS/HIPEC treatment modality has demonstrated short-term efficacy and security in colorectal cancer PC.